论文部分内容阅读
目的 观察新瑞普欣对于肾功能不全者患者使用的安全性。方法 选择 30例稳定的肾功能减退患者 ,按内生肌酐清除率 (Ccr)分成肾功能不全组和肾功能衰竭组 ,分别测定血常规、尿常规、肝、肾功能等指标。结果 两组患者使用新瑞普欣治疗后 ,与治疗前相比 ,血白细胞总数、中性粒细胞百分率均明显下降 (P <0 .0 1) ,其中 17例合并泌尿系感染患者尿常规中白细胞总数 ,治疗后与治疗前相比 ,也明显下降 ,肝、肾功能治疗前后无明显改变 ,Ccr变化也不明显。结论 对肾功能不全患者使用新瑞普欣具有较好的安全性。
Objective To observe the safety of neo-Ropin in patients with renal insufficiency. Methods Thirty patients with stable renal dysfunction were divided into renal dysfunction group and renal failure group according to endogenous creatinine clearance (Ccr), and blood routine, urine routine, liver and renal function were measured. Results After treatment with neo-ruupuxin, the total number of leukocytes and the percentage of neutrophils were significantly decreased in both groups (P <0.01), and among the 17 patients with urinary tract infection, the urinary routine The total number of white blood cells, after treatment compared with before treatment, also significantly decreased, liver and kidney function before and after treatment did not change significantly, Ccr change was not obvious. Conclusions Patients with renal insufficiency have good safety with nesreruxin.